Read more here
Welcome to OncoGeneX
News & Events
Thursday, May 23 2013
OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in...
Wednesday, May 22 2013
OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting
Wednesday, May 22 2013
OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting
OncoGenex is a biopharmaceutical company uniquely focused on cancer treatment resistance. We are committed to the development and commercialization of first-in-class, innovative therapies that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
Product Pipeline
Phase Three
Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
Information:
For PatientsFor PhysiciansFor InvestorsPhase Two
OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
